Page 119 - MI-2-1

Microbes & Immunity Anti-mouse CXCR5 monoclonal antibody

differentiation. Nat Immunol. 2001;2(2):102-107. development via mRNA decay catalyzed by the CCR4-NOT
Complex. Front Immunol. 2021;12:715675.
doi: 10.1038/84205
doi: 10.3389/fimmu.2021.715675
28. Allegretti M, Cesta MC, Locati M. Allosteric modulation of
chemoattractant receptors. Front Immunol. 2016;7:170. 40. Su Z, Chen L, Niu Q, Yang B, Huang Z. Association of
gene polymorphisms in CXC chemokine receptor 5 with
doi: 10.3389/fimmu.2016.00170
rheumatoid arthritis susceptibility. Iran J Allergy Asthma
29. Schulz O, Hammerschmidt SI, Moschovakis GL, Förster R. Immunol. 2022;21(5):537-548.
Chemokines and chemokine receptors in lymphoid tissue
dynamics. Annu Rev Immunol. 2016;34:203-242. doi: 10.18502/ijaai.v21i5.11041
41. Shi J, Hou S, Fang Q, et al. PD-1 controls follicular T helper
doi: 10.1146/annurev-immunol-041015-055649
cell positioning and function. Immunity. 2018;49(2):264-
30. Stone MJ, Hayward JA, Huang C, Huma ZE, Sanchez J. 274.e264.
Mechanisms of regulation of the chemokine-receptor
network. Int J Mol Sci. 2017;18(2):342. doi: 10.1016/j.immuni.2018.06.012
42. Kazanietz MG, Durando M, Cooke M. CXCL13 and its
doi: 10.3390/ijms18020342
receptor CXCR5 in cancer: Inflammation, immune response,
31. López-Cotarelo P, Gómez-Moreira C, Criado- and beyond. Front Endocrinol (Lausanne). 2019;10:471.
García O, Sánchez L, Rodríguez-Fernández JL. Beyond doi: 10.3389/fendo.2019.00471
chemoattraction: Multifunctionality of chemokine receptors
in leukocytes. Trends Immunol. 2017;38(12):927-941. 43. Shiels MS, Pfeiffer RM, Hildesheim A, et al. Circulating
inflammation markers and prospective risk for lung cancer.
doi: 10.1016/j.it.2017.08.004
J Natl Cancer Inst. 2013;105(24):1871-1880.
32. Laufer JM, Legler DF. Beyond migration-Chemokines
in lymphocyte priming, differentiation, and modulating doi: 10.1093/jnci/djt309
effector functions. J Leukoc Biol. 2018;104(2):301-312. 44. Eide HA, Halvorsen AR, Sandhu V, et al. Non-small cell lung
cancer is characterised by a distinct inflammatory signature
doi: 10.1002/jlb.2mr1217-494r
in serum compared with chronic obstructive pulmonary
33. Cecchinato V, Uguccioni M. Insight on the regulation of disease. Clin Transl Immunol. 2016;5(11):e109.
chemokine activities. J Leukoc Biol. 2018;104(2):295-300.
doi: 10.1038/cti.2016.65
doi: 10.1002/jlb.3mr0118-014r
45. Hussain M, Adah D, Tariq M, et al. CXCL13/CXCR5
34. Rajarathnam K, Schnoor M, Richardson RM, Rajagopal S. signaling axis in cancer. Life Sci. 2019;227:175-186.
How do chemokines navigate neutrophils to the target doi: 10.1016/j.lfs.2019.04.053
site: Dissecting the structural mechanisms and signaling
pathways. Cell Signal. 2019;54:69-80. 46. Panse J, Friedrichs K, Marx A, et al. Chemokine CXCL13 is
overexpressed in the tumour tissue and in the peripheral blood
doi: 10.1016/j.cellsig.2018.11.004
of breast cancer patients. Br J Cancer. 2008;99(6):930-938.
35. Groom JR. Regulators of T-cell fate: Integration of cell
migration, differentiation and function. Immunol Rev. doi: 10.1038/sj.bjc.6604621
2019;289(1):101-114. 47. Singh S, Singh R, Sharma PK, et al. Serum CXCL13
positively correlates with prostatic disease, prostate-specific
doi: 10.1111/imr.12742
antigen and mediates prostate cancer cell invasion, integrin
36. Graham GJ, Handel TM, Proudfoot AEI. Leukocyte clustering and cell adhesion. Cancer Lett. 2009;283(1):29-35.
adhesion: Reconceptualizing chemokine presentation by doi: 10.1016/j.canlet.2009.03.022
glycosaminoglycans. Trends Immunol. 2019;40(6):472-481.
48. Ouchida T, Isoda Y, Nakamura T, et al. Establishment of a
doi: 10.1016/j.it.2019.03.009
novel anti-mouse CCR1 monoclonal antibody C(1)Mab-6.
37. Michael M, Vermeren S. A neutrophil-centric view of Monoclon Antib Immunodiagn Immunother. 2024;43(2):67-74.
chemotaxis. Essays Biochem. 2019;63(5):607-618.
doi: 10.1089/mab.2023.0032
doi: 10.1042/ebc20190011
49. Asano T, Suzuki H, Tanaka T, et al. C(3)Mab-3: A monoclonal
38. Crijns H, Vanheule V, Proost P. Targeting chemokine- antibody for mouse CC chemokine receptor 3 for flow
glycosaminoglycan interactions to inhibit inflammation. cytometry. Monoclon Antib Immunodiagn Immunother.
Front Immunol. 2020;11:483. 2022;41(2):74-79.
doi: 10.3389/fimmu.2020.00483 doi: 10.1089/mab.2021.0062
39. Akiyama T, Yamamoto T. Regulation of early lymphocyte 50. Li G, Tanaka T, Suzuki H, Kaneko MK, Kato Y. Cx1Mab-1:

Volume 2 Issue 1 (2025) 111 doi: 10.36922/mi.5664